Last week’s top five stocks that were bought by their CEOs were Ultralife Corp., Black Diamond, Alnylam Pharmaceuticals, CytRx Corp. and General Finance Corp. According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below:
Ultralife Corp. (ULBI, Financial): President and CEO Michael D. Popielec Bought 40,000 Shares
President and CEO of Ultralife Corp. (ULBI) Michael D. Popielec bought 40,000 shares on 02/23/2012 at an average price of $5.13. Ultralife Corp., which began as a battery company, now offers products and services ranging from portable and standby power solutions to communications and electronics systems. Ultralife Corp. has a market cap of $88.87 million; its shares were traded at around $5.13 with a P/E ratio of 85.5 and P/S ratio of 0.64.
Ultralife recently reported operating income from continuing operations of $2.1 million on revenue of $31.4 million for the quarter ended December 31, 2011. For the fourth quarter of 2010, the company reported operating income from continuing operations of $3 million on revenue of $45.9 million.
Director James A. Croce sold 5,000 shares of ULBI stock on 02/22/2012 at the average price of $4.85. James A. Croce owns at least 13,901 shares after this. The price of the stock has increased by 5.77% since.
Black Diamond (BDE, Financial): CEO and President Peter R. Metcalf Bought 13,333 Shares
CEO and President of Black Diamond (BDE) Peter R. Metcalf bought 13,333 shares on 02/22/2012 at an average price of $8.17. Black Diamond Inc., formerly known as Clarus Corporation, operates as a manufacturer and distributor of outdoor recreation equipment and active lifestyle products. Black Diamond has a market cap of $177.8 million; its shares were traded at around $8.17 with a P/E ratio of 48.06 and P/S ratio of 1.6.
Black Diamond recently reported preliminary results for the fourth quarter and full year ended Dec. 31, 2011. The company expects to report fourth quarter 2011 consolidated sales of more than $36 million, up at least 6% from $34 million in the year-ago quarter.
Director Nicolas Sokolow bought 66,667 shares of BDE stock on 02/22/2012 at the average price of $7.5. Nicolas Sokolow owns at least 377,567 shares after this. The price of the stock has increased by 8.93% since. Other insiders have also increased their positions in the company.
Alnylam Pharma (ALNY, Financial): CEO John Maraganore Bought 5,581 Shares
CEO of Alnylam Pharma (ALNY) John Maraganore bought 5,581 shares on 02/21/2012 at an average price of $13.42. Alnylam Pharmaceuticals Inc. is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. Alnylam Pharma has a market cap of $573.4 million; its shares were traded at around $13.42 with and P/S ratio of 6.93.
ALNY recently reported its fourth quarter and full year 2011 financial results. Revenues were $20.5 million for the fourth quarter of 2011, as compared to $21.2 million for the same period last year.
Senior Vice President and Chief Business Officer Laurence Reid bought 930 shares of ALNY stock on 02/21/2012 at the average price of $10.75. Laurence Reid owns at least 12,733 shares after this. The price of the stock has increased by 24.84% since. Other insiders have also increased their positions in the company.
CytRx Corp. (CYTR, Financial): CEO Steven A. Kriegsman Bought 158,676 Shares
CEO of CytRx Corp (CYTR) Steven A. Kriegsman bought 158,676 shares on 02/23/2012 at an average price of $0.34. CytRx CORP. is engaged in the development and commercialization of pharmaceutical related products and services including human therapeutics focused on high-value critical-care therapies. CytRx Corp has a market cap of $50.47 million; its shares were traded at around $0.34 with and P/S ratio of 504.65.
CFO John Y. Caloz bought 31,792 shares of CYTR stock on 02/23/2012 at the average price of $0.32. John Y. Caloz owns at least 31,792 shares after this.
General Finance (GFN, Financial): Director and CEO, 10% Owner Ronald Valenta Bought 16,450 Shares
Director and CEO, 10% Owner of General Finance (GFN) Ronald Valenta bought 16,450 shares on 02/23/2012 at an average price of $2.57. General Finance has a market cap of $56.57 million; its shares were traded at around $2.57 with a P/E ratio of 2.99 and P/S ratio of 0.31.
General Finance recently reported its first quarter fiscal year 2012 results. The company reported that its total revenues for the quarter were $52.8 million, or an increase of 22% over the first quarter of 2011. Additionally, adjusted EDITDA was $11.4 million, or an increase of 34% over the first quarter of fiscal year 2011.
General Counsel, VP and Secretary Christopher A. Wilson bought 4,000 shares of GFN stock on 02/23/2012 at the average price of $2.78. Christopher A. Wilson owns at least 41,300 shares after this. The price of the stock has decreased by 7.55% since.
Ultralife Corp. (ULBI, Financial): President and CEO Michael D. Popielec Bought 40,000 Shares
President and CEO of Ultralife Corp. (ULBI) Michael D. Popielec bought 40,000 shares on 02/23/2012 at an average price of $5.13. Ultralife Corp., which began as a battery company, now offers products and services ranging from portable and standby power solutions to communications and electronics systems. Ultralife Corp. has a market cap of $88.87 million; its shares were traded at around $5.13 with a P/E ratio of 85.5 and P/S ratio of 0.64.
Ultralife recently reported operating income from continuing operations of $2.1 million on revenue of $31.4 million for the quarter ended December 31, 2011. For the fourth quarter of 2010, the company reported operating income from continuing operations of $3 million on revenue of $45.9 million.
Director James A. Croce sold 5,000 shares of ULBI stock on 02/22/2012 at the average price of $4.85. James A. Croce owns at least 13,901 shares after this. The price of the stock has increased by 5.77% since.
Black Diamond (BDE, Financial): CEO and President Peter R. Metcalf Bought 13,333 Shares
CEO and President of Black Diamond (BDE) Peter R. Metcalf bought 13,333 shares on 02/22/2012 at an average price of $8.17. Black Diamond Inc., formerly known as Clarus Corporation, operates as a manufacturer and distributor of outdoor recreation equipment and active lifestyle products. Black Diamond has a market cap of $177.8 million; its shares were traded at around $8.17 with a P/E ratio of 48.06 and P/S ratio of 1.6.
Black Diamond recently reported preliminary results for the fourth quarter and full year ended Dec. 31, 2011. The company expects to report fourth quarter 2011 consolidated sales of more than $36 million, up at least 6% from $34 million in the year-ago quarter.
Director Nicolas Sokolow bought 66,667 shares of BDE stock on 02/22/2012 at the average price of $7.5. Nicolas Sokolow owns at least 377,567 shares after this. The price of the stock has increased by 8.93% since. Other insiders have also increased their positions in the company.
Alnylam Pharma (ALNY, Financial): CEO John Maraganore Bought 5,581 Shares
CEO of Alnylam Pharma (ALNY) John Maraganore bought 5,581 shares on 02/21/2012 at an average price of $13.42. Alnylam Pharmaceuticals Inc. is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. Alnylam Pharma has a market cap of $573.4 million; its shares were traded at around $13.42 with and P/S ratio of 6.93.
ALNY recently reported its fourth quarter and full year 2011 financial results. Revenues were $20.5 million for the fourth quarter of 2011, as compared to $21.2 million for the same period last year.
Senior Vice President and Chief Business Officer Laurence Reid bought 930 shares of ALNY stock on 02/21/2012 at the average price of $10.75. Laurence Reid owns at least 12,733 shares after this. The price of the stock has increased by 24.84% since. Other insiders have also increased their positions in the company.
CytRx Corp. (CYTR, Financial): CEO Steven A. Kriegsman Bought 158,676 Shares
CEO of CytRx Corp (CYTR) Steven A. Kriegsman bought 158,676 shares on 02/23/2012 at an average price of $0.34. CytRx CORP. is engaged in the development and commercialization of pharmaceutical related products and services including human therapeutics focused on high-value critical-care therapies. CytRx Corp has a market cap of $50.47 million; its shares were traded at around $0.34 with and P/S ratio of 504.65.
CFO John Y. Caloz bought 31,792 shares of CYTR stock on 02/23/2012 at the average price of $0.32. John Y. Caloz owns at least 31,792 shares after this.
General Finance (GFN, Financial): Director and CEO, 10% Owner Ronald Valenta Bought 16,450 Shares
Director and CEO, 10% Owner of General Finance (GFN) Ronald Valenta bought 16,450 shares on 02/23/2012 at an average price of $2.57. General Finance has a market cap of $56.57 million; its shares were traded at around $2.57 with a P/E ratio of 2.99 and P/S ratio of 0.31.
General Finance recently reported its first quarter fiscal year 2012 results. The company reported that its total revenues for the quarter were $52.8 million, or an increase of 22% over the first quarter of 2011. Additionally, adjusted EDITDA was $11.4 million, or an increase of 34% over the first quarter of fiscal year 2011.
General Counsel, VP and Secretary Christopher A. Wilson bought 4,000 shares of GFN stock on 02/23/2012 at the average price of $2.78. Christopher A. Wilson owns at least 41,300 shares after this. The price of the stock has decreased by 7.55% since.
